| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Cefprozil is a cephalosporin antibiotic. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections. |
| Indication |
For the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph |
| Pharmacology |
Cefprozil, a semisynthetic, second-generation cephalosporin, is used to treat otitis media, soft-tissue infections, and respiratory tract infections. |
| Toxicity |
Single 5000 mg/kg oral doses of cefprozil caused no mortality or signs of toxicity in adult, weaning or neonatal rats, or adult mice. A single oral dose of 3000 mg/kg caused diarrhea and loss of appetite in cynomolgus monkeys, but no mortality. |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Biotransformation |
Cefprozil is eliminated primarily by the kidneys |
| Absorption |
Oral bioavailability is approximately 95%. |
| Half Life |
1.3 hours |
| Protein Binding |
36% |
| Distribution |
* 0.23 L/kg |
| Clearance |
* 3 mL/min/kg [fasting subjects] |
| External Links |
|
|